Featured Research

from universities, journals, and other organizations

Immune responses to tetanus vaccine unchanged for RA patients on rituximab

Date:
January 6, 2010
Source:
Wiley-Blackwell
Summary:
Researchers have determined that immune responses to the tetanus vaccine were not changed when rituximab in combination with methotrexate (MTX) was compared with MTX alone in patients with rheumatoid arthritis (RA). Responses to a pneumococcal vaccination, however, were reduced in RA patients with rituximab.

Researchers from Johns Hopkins University determined that immune responses to the tetanus vaccine were not changed when rituximab in combination with methotrexate (MTX) was compared with MTX alone in patients with rheumatoid arthritis (RA). Responses to a pneumococcal vaccination (Pneumovax® pneumonia vaccine), however, were reduced in RA patients with rituximab.

Complete findings of this study are published in the January 2010 issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

According to the Centers for Disease Control and Prevention (CDC), RA affects 1.3 million adults in the U.S. (2005). RA patients may be at an increased risk of infection because of impaired immune function due to the disease as well as from the use of immunsuppressive medications. As a result, vaccinations against infections are an essential part of rheumatic disease management. How immunosuppressive agents alter the effectiveness of vaccines in RA patients was the focus of the clinical trial led by Clifton O. Bingham III, M.D.

The controlled study enrolled 103 RA patients from 26 centers in the U.S. between January 2006 and December 2007. Patients treated with a stable dose (10-25 mg/week) of MTX were randomly allocated to two groups: placebo and treatment with rituximab (2 x 1000 mg given two weeks apart). Both groups were immunized with the tetanus and pneumococcal vaccines along with keyhole limpet hemocyanin (KLH) to evaluate humoral immunity and skin tested with Candida albicans to evaluate the cellular immune response.

Results indicate that 39.1% of patients in the rituximab+MTX group and 42.3% of MTX-only patients demonstrated a 4-fold rise in the anti-tetanus IgG titer. A 2-fold rise was confirmed in 54.7% of rituximab-treated patients and 61.5% of subjects on MTX alone. The research demonstrates that RA patients given a tetanus vaccine responded the same to tetanus vaccination regardless of whether they received MTX alone or rituximab in combination with MTX.

Patients treated only with MTX had a greater response to the pneumonia vaccine compared with those also receiving rituximab. Researchers found that only 57% of patients treated with rituximab had a response to one type of pneumococcal vaccine (Pneumovax®) compared with 82% of MTX-only patients.

The ability to maintain a positive delayed-type hypersensitivity (DTH) response to the Candida albicans skin test was comparable in both groups with 77.4% of rituximab-treated patients and 70% of MTX-only patients responding. "Our study, the first to examine DTH responses, confirmed that rituximab had no incremental effect on the patient's ability to mount a DTH response," said Dr. Bingham.

Treatment with rituximab produces a rapid depletion of B cells from the circulation, impacting the body's immune function. This depleted B cell pool begins to recover approximately 6-9 months after the initial treatment with rituximab. In his editorial also published in Arthritis & Rheumatism, E. William St. Clair, M.D. from Duke University Medical Center highlighted the need for further research into the effects of rituximab treatment.

"Further studies similar to Bingham et al are necessary to understand the complex effects of rituximab therapy on immune responses," noted Dr. St. Clair. "This study only evaluated immunization responses approximately 6 months after rituximab was administered; the responses at earlier time points, based on animal studies and its mechanism of action, may have been further attenuated," St. Clair added.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal References:

  1. Bingham et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial. Arthritis & Rheumatism, 2010; 62 (1): 64 DOI: 10.1002/art.25034
  2. St.Clair et al. Good and bad memories following rituximab therapy. Arthritis & Rheumatism, 2010; 62 (1): 1 DOI: 10.1002/art.25039

Cite This Page:

Wiley-Blackwell. "Immune responses to tetanus vaccine unchanged for RA patients on rituximab." ScienceDaily. ScienceDaily, 6 January 2010. <www.sciencedaily.com/releases/2010/01/100106095047.htm>.
Wiley-Blackwell. (2010, January 6). Immune responses to tetanus vaccine unchanged for RA patients on rituximab. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2010/01/100106095047.htm
Wiley-Blackwell. "Immune responses to tetanus vaccine unchanged for RA patients on rituximab." ScienceDaily. www.sciencedaily.com/releases/2010/01/100106095047.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Ebola Virus Threatens West Africa

Deadly Ebola Virus Threatens West Africa

AP (July 28, 2014) — West African nations and international health organizations are working to contain the largest Ebola outbreak in history. It's one of the deadliest diseases known to man, but the CDC says it's unlikely to spread in the U.S. (July 28) Video provided by AP
Powered by NewsLook.com
$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) — A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Two Americans Contract Ebola in Liberia

Two Americans Contract Ebola in Liberia

Reuters - US Online Video (July 28, 2014) — Two American aid workers in Liberia test positive for Ebola while working to combat the deadliest outbreak of the virus ever. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) — Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins